Updates in HER2+ Breast Cancer
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses recent updates in the field of HER2+ breast cancer.
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses recent updates in the field of HER2+ breast cancer.
Clinical Pearls:
- There have been advances in HER2+ breast cancer within the past few years
- HER2+ breast caner used to be one of the worst breast cancers to have, but today it is considered to be a “favorable” type of cancer to have
- The risk of recurrence with early-stage HER2+ breast cancer is low, but advanced HER2+ breast cancer cannot be cured because patients ultimately become resistant to therapy
- The HER2 signaling pathway has variations in it from cancer cell to cancer cell that can make the signaling pathway impeded
- Pertuzumab, when combination with trastuzumab, binds to a different part of the HER2 receptor
- This combination, along with chemotherapy, can reduce the amount of recurrences over time
- Although progression-free survival is improved with this combination, patients ultimately become resistant
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
